Last month at ADA 2026

The Weight-Loss Drug That Beat Ozempic — and Lost a Quarter of Its Patients

When researchers presented the SYNCHRONIZE-1 Phase 3 results at the American Diabetes Association's 2026 Scientific Sessions in June, the headline number was hard to ignore: 16.6% mean weight loss at 76 weeks versus 3.2% for placebo. For context, that puts survodutide — the dual GLP-1/glucagon receptor agonist from Boehringer Ingelheim and Zealand Pharma — in the same tier as tirzepatide, the current benchmark for non-surgical weight loss. In the liver disease trial, SYNCHRONIZE-MASLD, the results were even more striking: 61% of survodutide patients achieved liver fat normalization, with 84.2% hitting a 30% or greater reduction. Those are the kinds of numbers that make hepatologists sit up straight. Then the fine print landed. In SYNCHRONIZE-1, 24% of patients on survodutide discontinued due to adverse events — compared with 5.4% on placebo. In the MASLD trial: 23.3% discontinuation. Nearly one in four patients couldn't finish the study. The most common reason was gastrointestinal side effects, accounting for roughly 19% of dropouts. Boehringer's response was swift and clinical: the tolerability profile was "consistent with the GLP-1 class." Critics were less sanguine.

The actual mechanism

It Targets Hunger and Your Liver at the Same Time — That's the Whole Bet

Survodutide (also known as BI 456906) works by hitting two receptors simultaneously: GLP-1 and glucagon. This matters because GLP-1 alone — the target of semaglutide and liraglutide — suppresses appetite and slows gastric emptying. Adding glucagon receptor agonism is supposed to stack a second metabolic effect on top: increased energy expenditure and, critically, direct action on liver fat metabolism via the hepatic glucagon pathway. That's the theoretical basis for the MASLD trial, where the liver fat results were the most dramatic in the GLP-1 class to date. The dual-agonist approach is a legitimate mechanistic hypothesis. [Published pharmacology data on PubMed](https://pubmed.ncbi.nlm.nih.gov/?term=Survodutide+BI+456906) shows the drug binds with high affinity to both receptors and has demonstrated dose-dependent effects in early human studies. The question that SYNCHRONIZE answered — partially — is what happens when you push the dose high enough to generate best-in-class efficacy: you may also generate best-in-class nausea.

What Phase 3 actually showed

Best-in-Class Liver Numbers. Worst-in-Class Dropout Rate.

Let's be specific about what the SYNCHRONIZE data does and does not establish. On efficacy, survodutide is genuinely impressive. A [Phase 3 dataset published on PubMed](https://pubmed.ncbi.nlm.nih.gov/41216778/) provides granular outcomes: 85.1% of patients on survodutide achieved at least 5% weight loss (versus approximately 40% on placebo), and the 16.6% mean weight loss figure compares favorably to tirzepatide's 15–22.5% range in the SURMOUNT trials. The liver data from SYNCHRONIZE-MASLD represents a potential differentiator: no other approved or late-stage GLP-1 agent has published a 61% liver fat normalization rate in a Phase 3 trial. But the tolerability numbers require context, not spin. "Consistent with the GLP-1 class" is technically defensible — GI side effects are the defining liability of all GLP-1 drugs — but a 24% discontinuation rate is not consistent with the class's best performers. Tirzepatide's SURMOUNT-1 discontinuation due to adverse events was approximately 6.4%. Semaglutide's STEP-1 trial saw roughly 7% discontinuation. Survodutide's 24% is roughly three to four times those figures. Whether that gap reflects dose selection problems (solvable) or a fundamental ceiling on dual GLP-1/glucagon tolerability (not solvable without a new molecule) is a question Boehringer will need to answer before regulators — and before physicians writing prescriptions.

Three weeks later

Boehringer Just Announced It's Already Working on a Next-Gen Replacement

On July 16, 2026 — three weeks after ADA presentations generated the dropout-rate headlines — [Boehringer Ingelheim announced](https://www.globenewswire.com/news-release/2026/07/16/3328210/0/en/Boehringer-Ingelheim-strengthens-obesity-pipeline-as-potential-first-in-class-triple-receptor-agonist-BI-3034701-enters-Phase-II-development.html) that its next-generation obesity drug, BI 3034701, had entered Phase II development. BI 3034701 is a triple agonist — it hits GLP-1, GIP, and NPY2 receptors simultaneously. NPY2 (neuropeptide Y receptor type 2) is a brain-hunger pathway target that several major programs have been eyeing as the next frontier for weight loss. Adding it to the GLP-1/GIP combination that already defines tirzepatide is a meaningful escalation. The announcement did not say survodutide was being shelved. Boehringer continues to call survodutide a cornerstone of their cardiometabolic pipeline, and active [clinical trials for survodutide](https://clinicaltrials.gov/search?term=Survodutide) are ongoing across NASH, heart failure, and other indications. But the timing was — let's say — notable. When a company announces its next-generation molecule three weeks after its current molecule's worst data lands, the strategic signal is not subtle. Boehringer is hedging.

Early human — PeptideFactCheck stance

Promising Mechanism, Difficult Tolerability, One Unanswered Question

The evidence on survodutide is exactly what "Early human" means: real human data, meaningful efficacy signals, genuine biological mechanism — and too many open questions to call it settled. The Phase 3 results confirmed the drug can produce substantial weight loss and exceptional liver fat reduction. They also raised a legitimate tolerability concern that distinguishes survodutide from its GLP-1 competitors. The central unresolved question is whether the dropout rate reflects dose optimization problems (solvable) or a fundamental ceiling on dual GLP-1/glucagon tolerability (not solvable without a new molecule). Boehringer's BI 3034701 announcement suggests they are, at minimum, preparing for the latter. That is not a death sentence for survodutide — drugs with meaningful efficacy in serious diseases have been approved with significant tolerability liabilities before — but it does complicate the approval pathway and the commercial argument once competitors are on formularies. The [FDA's broader concerns about unapproved GLP-1 drugs](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) are a useful reminder that even approved GLP-1 compounds carry regulatory complexity. Survodutide has not been submitted for approval. Watch the next Phase 3 readouts on tolerability modifications and the comparative positioning versus tirzepatide. Do not interpret the MASLD liver numbers as applicable to any current commercial product.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.